Shah Smital
- SEC CIK
- 0001808821
No open-market purchases or sales filed in the past year.
Current role at each company
- LYEL Lyell Immunopharma, Inc.Chief Fin. and Bus. Officeras of Mar 16, 2026
- PLRX Pliant Therapeutics, Inc.Directoras of Jun 17, 2024
- LENZ LENZ Therapeutics, Inc.Directoras of Jul 21, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Shah Smital as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
LENZ LENZ Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2021 (view filing) | Jun 29 | 2 days | Shah SmitalDirector | PPurchase | +5.88K | $17.00 | +$100.0K | New position5.88K after |